Fujimoto Hiroyuki
Urology Division, National Cancer Center Hospital.
Nihon Rinsho. 2005 Feb;63(2):271-8.
The efficacy of neoadjuvant hormone therapy and radical prostatectomy for cT1-2 prostate cancer have been reported to be negative from some randomized prospective studies. On the other hand, radical prostatectomy alone for cT3 prostate cancer is understood as out of indication because of high rate of positive surgical margin and PSA failure. Several investigators have examined the role of neoadjuvant hormone therapy before radical prostatectomy for cT3 prostate cancer to improve outcome. This document was reviewed the literature whether neoadjuvant hormone therapy is beneficial or not, for organ confined prostate cancer and for locally advanced prostate cancer, and presented our extended resection of prostate with neoadjuvant hormone therapy is improved the results in cT3 prostate cancer.
一些随机前瞻性研究报告称，新辅助激素治疗和根治性前列腺切除术对cT1-2期前列腺癌的疗效为阴性。另一方面，由于手术切缘阳性率和前列腺特异抗原（PSA）失败率较高，单纯根治性前列腺切除术治疗cT3期前列腺癌被认为超出了适应证范围。一些研究人员探讨了新辅助激素治疗在cT3期前列腺癌根治性前列腺切除术前的作用，以改善治疗效果。本文回顾了关于新辅助激素治疗对局限性前列腺癌和局部晚期前列腺癌是否有益的文献，并提出我们采用新辅助激素治疗的前列腺扩大切除术改善了cT3期前列腺癌的治疗结果。
